SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Sabizabulin is an investigational new drug that is being evaluated for the treatment of castration-resistant prostate cancer and in SARS-CoV-2 (COVID-19) infections. It is a tubulin polymerization inhibitor. Sabizabulin is chemical compound from the group of indole and imidazole derivatives that was first reported in 2012 by Dalton, Li, and Miller.
== Avoidance == In theory, avoidance is simply a matter of preventing hyperinsulinemia. In practice, the difficulty for a diabetic person to aggressively dose insulin to keep blood sugars levels close to normal — while adjusting the insulin regimen to the demands of exercise, stress, and wellness — can practically assure occasional hyperinsulinemia. The pharmacokinetic imperfections of all insulin replacement regimens is a severe limitation. Some practical behaviors which are useful in avoiding chronic Somogyi rebound are:
== Recording == The recording of Dirt began in the spring of 1992. Producer Dave Jerden, who had previously worked with the band on their debut, Facelift, wanted to work with them again. He admired Layne Staley's lyrics and voice, and Jerry Cantrell's guitar riffs. The track "Would?" produced, engineered, and mixed by Rick Parashar, was recorded before the album, and first appeared on the soundtrack to the 1992 movie Singles. Dirt was recorded at Eldorado Recording Studios in Burbank, London Bridge Studio in Seattle, and One on One Studios in Los Angeles from April to July 1992. Dirt was recorded during the Los Angeles riots that erupted following the acquittal of four LAPD officers caught on camera beating unarmed black motorist Rodney King. The riots started on the first day of recording. The band was watching television when the verdict for the incident was announced. Jerry Cantrell was in a store buying some beer when a man came in and started looting the place. Cantrell also got stuck in traffic and saw people pulling each other out of their cars and beating them. The band tried to get out of Los Angeles without getting hurt while residents were protesting against police brutality. They took Slayer vocalist Tom Araya with them and went to the Joshua Tree desert for four or five days until things calmed down, then moved back into the studio and started recording the album. While recording the album, Staley, who had previously checked out of rehab, quickly went back to using heroin. Staley later went cold-turkey on his own while reading The Bad Place by Dean Koontz.
Unlike channel proteins which only transport substances through membranes passively, carrier proteins can transport ions and molecules either passively through facilitated diffusion, or via secondary active transport. A carrier protein is required to move particles from areas of low concentration to areas of high concentration. These carrier proteins have receptors that bind to a specific molecule (substrate) needing transport. The molecule or ion to be transported (the substrate) must first bind at a binding site at the carrier molecule, with a certain binding affinity. Following binding, and while the binding site is facing the same way, the carrier will capture or occlude (take in and retain) the substrate within its molecular structure and cause an internal translocation so that the opening in the protein now faces the other side of the plasma membrane. The carrier protein substrate is released at that site, according to its binding affinity there.
as shown above for one decay. The solution can be found by the integration factor method, where the integrating factor is eλBt. This case is perhaps the most useful since it can derive both the one-decay equation (above) and the equation for multi-decay chains (below) more directly.
Sources: en.wikipedia.org
==== Usage in global industry ==== Direct oxidation of ethylene was patented by Lefort in 1931. This method was repeatedly modified for industrial use, and at least four major variations are known. They all use oxidation by oxygen or air and a silver-based catalyst, but differ in the technological details and hardware implementations. Union Carbide (currently a division of Dow Chemical Company) was the first company to develop the direct oxidation process. A similar production method was developed by Scientific Design Co., but it received wider use because of the licensing system – it accounts for 25% of the world's production and for 75% of world's licensed production of ethylene oxide. A proprietary variation of this method is used by Japan Catalytic Chemical Co., which adapted synthesis of both ethylene oxide and ethylene glycol in a single industrial complex. A different modification was developed Shell International Chemicals BV. Their method is rather flexible with regard to the specific requirements of specific industries; it is characterized by high selectivity with respect to the ethylene oxide product and long lifetime of the catalyst (3 years). It accounts for about 40% of global production. Older factories typically use air for oxidation whereas newer plants and processes, such as METEOR and Japan Catalytic, favor oxygen.
Imino acids are structurally related to amino acids, which have amino group instead of imine—a difference of single vs double-bond between nitrogen and carbon. The simplest example is dehydroglycine. D-Amino acid oxidase is an enzyme that is able to convert amino acids into imino acids. Also the direct biosynthetic precursor to the amino acid proline is the imino acid (S)-Δ1-pyrroline-5-carboxylate (P5C).
== Diagnostic == Dozens of congenital metabolic diseases are now detectable by newborn screening tests, especially expanded testing using mass spectrometry. Gas chromatography–mass spectrometry-based technology with an integrated analytics system has now made it possible to test a newborn for over 100 mm genetic metabolic disorders. Because of the multiplicity of conditions, many different diagnostic tests are used for screening. An abnormal result is often followed by a subsequent "definitive test" to confirm the suspected diagnosis.
== Disorders == Women who have been on relaxin treatment during unrelated clinical trials have experienced heavier bleeding during their menstrual cycle, suggesting that relaxin levels could play a role in abnormal uterine bleeding. However, more research is needed to confirm relaxin as a direct cause. A lower expression of relaxin has been found amongst women who have endometriosis. The research in this area is limited and more studying of relaxin's contribution could contribute greatly to the understanding of endometriosis. Specific disorders related to relaxin have not been heavily described, yet a link to scleroderma and fibromyalgia has also been suggested.
In 2023, the US State Department announced plans to launch a "global coalition to address synthetic drug threats", with more than 80 countries expected to join. That April, Anne Milgram, head of the DEA since 2021, stated to Congress that two Mexican drug cartels posed "the greatest criminal threat the United States has ever faced." Supporting a DEA budget request of $3.7 billion for 2024, Milgram cited fentanyl in the "most devastating drug crisis in our nation's history." In October 2023, OFAC sanctioned a China-based network of fentanyl manufacturers and distributors. The drug is usually manufactured in China, then shipped to Mexico, where it is processed and packaged, which is then smuggled into the US by Mexican drug cartels. In January 2024, the DEA confirmed that it was reviewing the classification of cannabis as a Schedule I narcotic. Days later, documents were released from the Department of Health and Human Services stating that cannabis has "a currently accepted medical use" in the US and a "potential for abuse less than the drugs or other substances in Schedules I and II." On 30 April, indicating a DEA decision, the Justice Department announced, "Today, the Attorney General circulated a proposal to reclassify marijuana from Schedule I to Schedule III. Once published by the Federal Register, it will initiate a formal rulemaking process as prescribed by Congress in the Controlled Substances Act." Schedule III drugs, considered to have moderate to low potential for dependence, include ketamine, anabolic steroids, testosterone, and Tylenol with codeine.
Sources: en.wikipedia.org
== Automation == There have been some efforts in automating the generation of inclusion lists through the solution of external software. In 2010, Wu et al. introduced a semi-automatic method in an effort of identifying low-abundance glyco-peptide. They implemented the automation through iterative experiments and the open-source software GLYPID. With minor modification, this approach can be used in analyzing any other simple or complex samples. In addition to the advantage mentioned before, this semi-automated approach also saves substantial amount of time and efforts for scientists in manually picking ions and re-calibrating instruments.
Pizotifen is a serotonin antagonist acting mainly at the 5-HT2A, 5-HT2B, and 5-HT2C receptors. It also has some activity as an antihistamine as well as some anticholinergic activity. The drug binds non-selectively to many targets, including serotonin, dopamine, adrenergic, histamine, and muscarinic acetylcholine receptors. Besides its serotonin 5-HT2 receptor antagonism, pizotifen is a low-potency moderate-efficacy partial agonist of the serotonin 5-HT1A receptor. Pizotifen is able to dose-dependently and fully antagonize the discriminative stimulus effects of the serotonin–norepinephrine–dopamine releasing agent and serotonin 5-HT2 receptor agonist MDMA in rodent drug discrimination tests. Conversely, the related drug cyproheptadine was only partially effective and clozapine was ineffective. All three of these agents, pizotifen, cyproheptadine, and clozapine act as non-selective monoamine receptor antagonists. Pizotifen also fully blocks the effects of serotonergic psychedelics, including LSD, mescaline, 5-MeO-DMT, and DOM, in drug discrimination tests. The antimigraine activity of pizotifen might be specifically due to serotonin 5-HT2B receptor blockade.
== Adverse effects == In the treatment of psoriasis, the most common adverse events are gastrointestinal events, flushing and lymphopenia, which are usually mild. Other adverse events include progressive multifocal leukoencephalopathy (PML) and Fanconi syndrome, which are considered rare. PML is probably caused by a combination of factors. A previous infection with the John-Cunningham virus (JCV) is considered a prerequisite for the development of PML. In a PML review, all confirmed cases were of patients exposed to periods of varying lymphopenia. For multiple sclerosis, adverse effects include flushing and gastrointestinal events, such as diarrhoea, nausea and upper abdominal pain. The drug label includes warnings about the risk of anaphylaxis and angioedema, PML, lymphopenia and liver damage. There is no information on how dimethyl fumarate affects the fetus during pregnancy; in animal tests there was fetal harm at clinically relevant doses.
=== Final weeks on the Gulf Coast === Filming resumed on July 19. The sandpit fight scene between Bosworth and pro wrestler Tom Magee was shot in Bay St. Louis. It was aborted after a first attempt where Bosworth clipped Magee's cheek with a punch, and finished two weeks later on August 9. While a King Features gossip column claimed that the botch had led to a real scuffle, Bosworth himself assured that the accident had been handled in a civil manner by both. The final scene shot on the Gulf Coast was a gas station explosion on Daisy Vestry Road in Latimer on August 10.
=== ERAP1 allosteric site inhibitors === Compound GSK235 Methyl (3R,4R)-1-(3-cyano-4-methyl-6-((4-methyltetrahydro-2H-pyran-4-yl)amino)pyridin-2-yl)-4-isopropylpyrrolidine-3-carboxylate was reported to be a potent, selective and orally available inhibitor of ERAP1. In vivo experiments showed efficacy in tumor growth control in a mouse model as well as therapeutic benefit in an inflammatory autoimmunity murine model. This compound ("GSK235") is a potent in vivo tool for exploring ERAP1 biology and possible therapeutic applications.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.